• Target disease: Visceral leishmaniasis (VL)
  • Main partners (since project start): Takeda Pharmaceutical Company Ltd., Japan
  • Project start: 2017
  • Funding (since project start): Department for International Development (DFID), UK; Global Health Innovative Technology (GHIT) Fund, Japan.
  • Project status: Completed


Overall objective:

  • Progress DNDi-5561, a selected aminopyrazole compound, to Phase I clinical trials and realize some activities including formulation development, drug product manufacture and start single ascending dose stage of first-in-human.


DNDI-5561 is the most advanced compound of the aminopyrazole series. DNDi developed the series from a single high-throughput screening hit, which was originally identified in an in vitro screen of Pfizer’s compound library. A hit-to-lead project conducted by DNDi produced improved leads with activity in animal models of leishmaniasis. The optimization of these leads to produce DNDI-5561 was achieved in a partnership between DNDi, Takeda, and the GHIT Fund.


Pre-clinical studies to enable a first-in-human study (Phase I) started in February 2018 and should be completed by the end of 2019

Following positive results of efficacy and safety studies in animal model, DNDI-5561 was selected as pre-clinical candidate in October 2017.


Last update: August 2019